Joinn Laboratories (HKG:6127, SHA:603127) posted a profit attributable to equity shareholders of 60.9 million yuan for the first half of 2025, reversing a loss of 169.7 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.
Hong Kong-listed shares of the pharma research company fell nearly 5% in afternoon trade on Wednesday.
Earnings per share came in at 0.08 yuan, compared with a loss per share of 0.23 yuan in the prior-year period.
Revenue fell to 668.6 million yuan from 849.4 million yuan.